Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Net Income towards Common Stockholders: 2010-2018

Historic Net Income towards Common Stockholders for EyePoint Pharmaceuticals (EYPT) over the last 9 years, with Jun 2018 value amounting to -$53.2 million.

  • EyePoint Pharmaceuticals' Net Income towards Common Stockholders fell 139.24% to -$14.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$34.6 million, marking a year-over-year decrease of 99.88%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.64% down from last year.
  • Per EyePoint Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$53.2 million for FY2018, which was down 187.64% from -$18.5 million recorded in FY2017.
  • In the past 5 years, EyePoint Pharmaceuticals' Net Income towards Common Stockholders registered a high of $8.0 million during FY2015, and its lowest value of -$53.2 million during FY2018.
  • For the 3-year period, EyePoint Pharmaceuticals' Net Income towards Common Stockholders averaged around -$31.1 million, with its median value being -$21.5 million (2016).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 160.08% in 2015, then plummeted by 368.53% in 2016.
  • Yearly analysis of 5 years shows EyePoint Pharmaceuticals' Net Income towards Common Stockholders stood at -$13.4 million in 2014, then surged by 160.08% to $8.0 million in 2015, then tumbled by 368.53% to -$21.5 million in 2016, then increased by 14.21% to -$18.5 million in 2017, then plummeted by 187.64% to -$53.2 million in 2018.